Replies to post #1872 on Enanta Pharmaceuticals Inc (ENTA)

[10nisman]

On today’s 1Q20 CC, ABBV said about half of the $200K guidance reduction stems from COVID-19 issues.

$200M

[DewDiligence]

ABBV’s 2Q20 Mavyret sales=$376M, -33% QoQ, -51% YoY—the decline was attributable to fewer new-patient starts during the COVID-19 pandemic:

https://news.abbvie.com/news/press-releases/abbvie-reports-second-quarter-2020-financial-results.htm

ABBV lowered full-year-2020 Mavyret sales to $2.1B (from the prior guidance of $2.3B), which implies 2H20 Mavyret sales of $1.0-1.1B. I.e., expected Mavyret sales during 2H20 will be almost equal to the run rate in the Jan 2020 (pre-COVID-19) guidance.